How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,237 results for

Thrombin Hemostatic

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1001. The FEIBA NovoSeven Comparative Study

, cross-over, multi-center study to investigate and compare the hemostatic effect and cost-efficacy of two different by-passing agents in the treatment of joint hemorrhages in subjects with severe hemophilia A and inhibitors. The study is designed as a clinical equivalency trial. Condition or disease Intervention/treatment Phase Severe Hemophilia A With an Inhibitor Drug: FEIBA and NovoSeven Not Applicable Detailed Description: The incidence of inhibitors among people with severe hemophilia A has been (...) Comparative Study Study Start Date : July 2000 Actual Study Completion Date : June 2005 Resource links provided by the National Library of Medicine related topics: related topics: available for: resources: Arms and Interventions Go to Outcome Measures Go to Primary Outcome Measures : -The hemostatic effect of treatment with a single dose of FEIBA with that of two doses of NovoSeven on joint hemorrhages after 6 hours. Secondary Outcome Measures : The hemostatic effect of treatment after 2, 12, 24 36

2005 Clinical Trials

1002. Prothrombin Complex Concentrate for Anticoagulant Reversal

Head Clinical Research & Development, CSL Behring Identifier: Other Study ID Numbers: BE1116_3001 First Posted: September 14, 2005 Last Update Posted: February 11, 2011 Last Verified: February 2011 Keywords provided by CSL Behring: Prothrombin Complex Concentrate Anticoagulant reversal Additional relevant MeSH terms: Layout table for MeSH terms Anticoagulants Thrombin Hemostatics Coagulants (...) 2006 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Outcome Measures Go to Primary Outcome Measures : Rapid reversal of anticoagulatory effect Secondary Outcome Measures : Clinical efficacy assessment (hemostatic effect) Increase of coagulation factors Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

2005 Clinical Trials

1003. Safety and Efficacy Study of Fibrin Sealant (FS 4IU) for Skin Graft Fixation and Wound Healing in Subjects With Burn Wounds

First Posted: September 13, 2005 Last Update Posted: October 20, 2006 Last Verified: October 2006 Additional relevant MeSH terms: Layout table for MeSH terms Burns Wounds and Injuries Thrombin Fibrin Tissue Adhesive Hemostatics Coagulants (...) treatment sites. Condition or disease Intervention/treatment Phase Burns Drug: Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 40 participants Allocation: Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Study to Assess the Safety and Efficacy of Fibrin Sealant (FS

2005 Clinical Trials

1004. Efficacy and Safety of Endoscopic Injection of Fibrin Sealant Versus Endoscopic Ligature for Bleeding Esophageal Varices

congenital or acquired coagulopathies of non-hepatic origin, who were currently participating or had participated in another study during the past 30 days or had already been included in this study once, who were treated with drugs to decrease portal vein pressure (somatostatin, somatostatin analogs, terlipressin, glycylpressin, except β-blockers and nitrates), who had shown an allergic reaction to thrombin or aprotinin, who had a heparin-induced thrombocytopenia Type I or Type II. Contacts and Locations (...) terms Varicose Veins Esophageal and Gastric Varices Vascular Diseases Cardiovascular Diseases Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Hypertension, Portal Liver Diseases Fibrin Tissue Adhesive Hemostatics Coagulants

2005 Clinical Trials

1005. Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

of the protein tissue factor (TF), which can be found in the sub-endothelial layer of the blood vessel and is a major component of atherosclerotic gruel. The exposure of TF following vascular damage or rupture of a coronary atherosclerotic plaque, results in the rapid formation of the enzymatic complex composed of TF and the serine protease factor VIIa (fVIIa/TF). The fVIIa/TF complex initiates an amplified cascade of proteolytic activation steps resulting in the formation of the serine protease thrombin (...) . The highly amplified generation of thrombin localized to the site of vascular damage or plaque rupture, coupled with the high-shear rheological environment of the coronary vessel, results in the activation and subsequent aggregation of platelets and the formation of an insoluble matrix of fibrin resulting in a platelet-rich thrombus. The critical role of the fVIIa/TF complex in the initiation of coronary thrombosis suggests that it may be an ideal target for inhibitors that will result in an attenuation

2005 Clinical Trials

1006. Efficacy of a Fibrin Sealant in Burn Surgery

. Both of these result in bleeding open wounds. Fibrin sealants may be of benefit in three aspects of burn surgery: as a hemostatic agent on excised burns, as a hemostatic agent on donor sites, and as a method of fixation of skin grafts to wounds. Skin grafts are routinely secured with surgical staples. Patients with large burns will commonly have hundreds, even thousands of staples used during the course of their care. Problems associated with the use of surgical staples include: discomfort upon (...) removal and staples become deeply embedded in the tissue. If effective in securing skin grafts, fibrin glue would directly benefit burn patients by decreasing the number of staples required, and thereby decreasing the number of retained staples. Fibrin sealant is produced from human fibrinogen and human thrombin from pooled plasma that is virally inactivated by a two-stage heating process. Subjects will serve as their own control. They will have an area of their wound treated with the fibrin sealant

2005 Clinical Trials

1007. The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress

) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin (...) Description: Background: Population based studies have established hemostatic abnormalities as independent risk factors for atherosclerosis and related adverse outcomes. These abnormalities are characterized as prothrombotic by elevated plasma levels of e.g. fibrinogen or D-dimer. Prothrombotic states appear to aggravate the impact of other risk factors, e.g. hypertension. Other epidemiologic studies have shown a sizable association between chronic mental stress (e. g. marital discord in women) or acute

2005 Clinical Trials

1008. Performance and Safety of Bone Substitute MBCP-FS in Maxillary Sinus Lift Procedures

Healthcare Corporation: Sinus augmentation Alloplastic bone substitute Hydroxyl apatite Additional relevant MeSH terms: Layout table for MeSH terms Thrombin Fibrin Tissue Adhesive Hemostatics Coagulants (...) Information provided by: Baxter Healthcare Corporation Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the performance and to monitor the safety of the bone substitute Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS) in Sinus Lift Procedures . This study will be conducted in two parts: part A evaluates safety and performance of MBCP-FS in bone regeneration i.e. the amount of new bone

2005 Clinical Trials

1009. Heparin Management During Cardiopulmonary Bypass in Children

Details Study Description Go to Brief Summary: We propose a comparison between between our standard ACT based heparin management protocol for children undergoing CPB and a patient-specific heparin concentration-based heparin management protocol. We hypothesize that a heparin concentration-based anticoagulation management protocol during CPB in children will result in more effective attenuation of hemostatic activation as reflected by decreased levels of thrombin formation and, ultimately, better (...) determined by the hepcon machine to a laboratory measured value. Blood samples for biochemical markers of hemostatic activation will be collected from all patients before the initiation of CPB after the administration of the initial heparin dose and after the conclusion of CPB before protamine infusion. The following biochemical markers of hemostatic activation will be measured: prothrombin fragment 1.2, fibrinopeptide A, free tissue factor pathway inhibitor, factor V, factor VIII, and beta

2005 Clinical Trials

1010. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. (Full text)

phosphorylation in vitro resulted in secondary downregulation of active alphaIIb beta3.These results lead to a new spatial model of thrombus formation, in which aggregated platelets ensure thrombus stability, whereas distinct patches of nonaggregated platelets effectuate procoagulant activity and generate thrombin and fibrin. Herein, the hemostatic activity of a developing thrombus is determined by the balance in formation of proaggregatory and procoagulant platelets. This balance is influenced (...) into separate aggregates, whereas distinct patches of nonaggregated platelets exposed phosphatidylserine. The latter platelet population had inactivated alphaIIb beta3 integrins and displayed increased binding of coagulation factors. Coated platelets, expressing serotonin binding sites, were not identified as a separate population. Thrombin generation and coagulation favored the transformation to phosphatidylserine-exposing platelets with inactivated integrins and reduced adhesion. Prolonged tyrosine

2007 Thrombosis and Vascular Biology PubMed abstract

1011. The Haemostatic Role of Tissue Factor Pathway Inhibitor. (Full text)

coagulation revolves around the activation and assembly of the components of the prothrombinase complex, which converts the inactive zymogen, prothrombin, into its active form, thrombin. This serine protease catalyzes the conversion of fibrinogen to fibrin, the structural scaffold that stabilizes platelet aggregates at sites of vascular injury. The extent of the hemostatic response is controlled by the action of inhibitory pathways, which ensure that thrombin activity and the spread of the hemostatic plug

2007 Thrombosis and Vascular Biology PubMed abstract

1012. In situ assays demonstrate that interferon-gamma suppresses infection-stimulated hepatic fibrin deposition by promoting fibrinolysis (Full text)

In situ assays demonstrate that interferon-gamma suppresses infection-stimulated hepatic fibrin deposition by promoting fibrinolysis Inflammatory cytokines potently impact hemostatic pathways during infection, but the tissue-specific regulation of coagulation and fibrinolysis complicates studies of the underlying mechanisms.Here, we describe assays that quantitatively measuring prothrombinase (PTase), protein C-ase (PCase) and plasminogen activator (PA) activities in situ, thereby facilitating (...) is associated with increased PCase activity and reduced PA activity during infection. Parallel analyses of hepatic gene expression reveal that IFN-gamma-deficiency is associated with increased expression of thrombomodulin (TM), a key component of the PCase, increased expression of thrombin-activatable fibrinolysis inhibitor (TAFI), a PC substrate, and reduced expression of urokinase PA (u-PA).These findings suggest that IFN-gamma suppresses infection-stimulated hepatic fibrin deposition by suppressing TM

2006 Journal of thrombosis and haemostasis : JTH PubMed abstract

1013. Fate of Membrane-bound Reactants and Products during the Activation of Human Prothrombin by Prothrombinase (Full text)

Fate of Membrane-bound Reactants and Products during the Activation of Human Prothrombin by Prothrombinase Membrane binding by prothrombin, mediated by its N-terminal fragment 1 (F1) domain, plays an essential role in its proteolytic activation by prothrombinase. Thrombin is produced in two cleavage reactions. One at Arg(320) yields the proteinase meizothrombin that retains membrane binding properties. The second, at Arg(271), yields thrombin and severs covalent linkage with the N-terminal (...) fragment 1.2 (F12) region. Covalent linkage with the membrane binding domain is also lost when prethrombin 2 (P2) and F12 are produced following initial cleavage at Arg(271). We show that at the physiological concentration of prothrombin, thrombin formation results in rapid release of the proteinase into solution. Product release from the surface can be explained by the weak interaction between the proteinase and F12 domains. In contrast, the zymogen intermediate P2, formed following cleavage at Arg

2008 The Journal of biological chemistry PubMed abstract


of individual C. oreganus helleri located in Riverside and San Bernardino counties of southern California were studied for their variation in their hemostatic activity. The results demonstrated that Riverside 2 and San Bernardino 1 venoms presented the highest lethal activity without hemorrhagic activity. In contrast, San Bernardino 2 and 3 venoms had the highest hemorrhagic and fibrinolytic activities with low lethal and coagulant activities. Riverside 1, Riverside 2 and San Bernardino 1 venoms presented (...) a significant thrombin-like activity. San Bernardino 2 and 3 venoms presented an insignificant thrombin-like activity. In relation to the fibrinolytic activity, San Bernardino 3 venom was the most active on fibrin plates, which was in turn neutralized by metal chelating inhibitors. These results demonstrate the differences amongst C. oreganus helleri venoms from close localities. A metalloproteinase, hellerase, was purified by anionic and cationic exchange chromatographies from San Bernardino 3 venom

2008 Comparative biochemistry and physiology. Toxicology & pharmacology : CBP PubMed abstract

1015. [Surgical versus non-surgical treatment for femoral pseudoaneurysms]. (Abstract)

Ugeskr Laeger 0141730 0041-5782 0 Hemostatics EC Thrombin IM Aneurysm, False diagnostic imaging surgery therapy Evidence-Based Medicine Femoral Artery diagnostic imaging surgery Hemostatics administration & dosage Humans Thrombin administration & dosage Ultrasonic Therapy Ultrasonography, Interventional 7 2007 4 12 9 0 2007 4 20 9 0 2007 4 12 9 0 ppublish 17425925 VP49346

2007 Ugeskrift for laeger

1016. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. (Abstract)

Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Hemostatic effects of the protease inhibitor aprotinin in cardiac surgery are well described, and recent evidence suggests an antithrombotic mechanism of aprotinin through inhibition of thrombin-mediated platelet activation. We hypothesized that aprotinin provides hemostasis while reducing vascular thrombosis by attenuating protease-dependent platelet function.Rabbits (3 to 4 kg) underwent carotid artery thrombosis (...) to thrombin was decreased by aprotinin therapy (59.2% +/- 3.0% versus 95.8% +/- 1.5%, p < 0.001), whereas protease-independent, ADP-induced platelet aggregation was unchanged with aprotinin. Incisional bleeding was not different between groups. In the aprotinin group, bleeding time was unchanged at baseline and then reduced for the duration of the experiment (35.0 +/- 4.7 seconds versus 76.8 +/- 6.4 seconds, p < 0.05).While providing hemostatic effects, aprotinin attenuates vascular thrombosis in part

2005 Annals of Thoracic Surgery

1017. Off-pump coronary artery bypass operation does not increase procoagulant and fibrinolytic activity: preliminary results. (Abstract)

were excluded. Nine patients underwent OPCAB operation and 16 underwent on-pump CABG. Activated clotting time (ACT) was adjusted to 250 seconds in OPCAB (81 +/- 18 [mean +/- SD] IU/kg heparin) and to more than 480 seconds in on-pump CABG (400 IU/kg heparin, additional 10,000 IU in pump prime). Perioperatively blood samples were collected and hematologic and hemostatic variables including fibrinopeptide A (FPA), fibrin monomer (FM), thrombin-antithrombin complex (TAT), and D-dimer were analyzed.Both (...) anticoagulation activation of coagulation and fibrinolysis is reduced in OPCAB compared with on-pump CABG. Reduced thrombin generation and reduced fibrinolytic activity in OPCAB indicates better preservation of hemostasis. We suggest the term "preserved hemostasis" instead of "hypercoagulant activity" with respect to OPCAB.

2004 Annals of Thoracic Surgery

1018. Clinical implication of plasma level of soluble fibrin monomer-fibrinogen complex in patients with abdominal aortic aneurysm. (Full text)

or nonimpregnated Dacron prosthesis. Plasma level of soluble FM-fibrinogen complex was measured before surgery and on days 1, 3, 5, 7, and 10 postoperatively by latex agglutination assay utilizing monoclonal antibody IF-43. Plasma levels of thrombin-antithrombin complex (TAT), D-dimer, alpha2-plasmin inhibitor-plasmin complex (PIC), and fibrinogen were also evaluated.The preoperative level of soluble FM-fibrinogen complex showed variation in the degree of hemostatic activation, with fair correlations with TAT (...) Clinical implication of plasma level of soluble fibrin monomer-fibrinogen complex in patients with abdominal aortic aneurysm. We prospectively studied the clinical implication of plasma level of soluble fibrin monomer (FM)-fibrinogen complex, a recently established molecular marker reflecting thrombin activity, in patients with abdominal aortic aneurysm (AAA) undergoing elective aortic repair.The study included 49 patients who underwent elective aneurysm repair using a gelatin-sealed

2005 Journal of Vascular Surgery PubMed abstract

1019. The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial. (Full text)

design. Thrombin-antithrombin complex and prothrombin fragments 1 and 2, both markers of thrombin generation; plasminogen activator inhibitor antigen and tissue plasminogen activator antigen, both markers of fibrinolysis; ankle-brachial pressure index (ABPI); and initial and absolute claudication distance (ACD) were measured at baseline and then 3 and 6 months after randomization.At 6 months, when compared with receiving BMT only, supervised exercise and cilostazol resulted in improvements in ABPI (...) of 18% and 13% and in ACD of 40% and 64%, respectively. The effects on ABPI and ACD of combining supervised exercise and cilostazol were additive. Supervised exercise, cilostazol, and supervised exercise combined with cilostazol had no significant effect on any of the four hemostatic markers.Treatment of IC by supervised exercise or cilostazol results in significant improvements in ABPI and ACD but has no demonstrable effect on the prothrombotic diathesis. This suggests that supervised exercise

2007 Journal of Vascular Surgery Controlled trial quality: uncertain PubMed abstract

1020. Activation of fibrinolytic pathways is associated with duration of supraceliac aortic cross-clamping. (Full text)

cross-clamping (IR AXC) for 60 minutes and 11 pigs that underwent SC AXC for 30 minutes served as controls. No heparin was used. Blood samples were drawn at baseline, 5 minutes before release of the aortic clamp, and 5, 30, and 60 minutes after unclamping. Prothrombin time, partial thromboplastin time, platelet count, and fibrinogen concentration were measured as basic tests of hemostatic function. Thrombin-antithrombin complexes were used to detect the presence of intravascular thrombosis (...) Activation of fibrinolytic pathways is associated with duration of supraceliac aortic cross-clamping. The cause of the coagulopathy seen with supraceliac aortic cross-clamping (SC AXC) is unclear. SC AXC for 30 minutes results in both clotting factor consumption and activation of fibrinolytic pathways. This study was undertaken to define the hemostatic alterations that occur with longer intervals of SC AXC.Seven pigs underwent SC AXC for 60 minutes. Five pigs that underwent infrarenal aortic

2004 Journal of Vascular Surgery PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>